Maryland Medical Assistance Program and Health Insurance - Nonopioid Drugs for the Treatment of Pain
SB 974 would require the Maryland Medical Assistance Program and certain private health coverage entities, including insurers, nonprofit health service plans, health maintenance organizations, and managed care organizations, to treat FDA-approved nonopioid pain medications at least as favorably as opioid or narcotic pain medications. The bill bars more restrictive prior authorization, step therapy, or fail-first requirements for nonopioid pain drugs than those applied to opioid or narcotic pain drugs, and it requires coverage for nonopioid pain drugs to the same extent as covered opioid or narcotic pain drugs.
The bill also adds a reporting and oversight component. By December 1, 2026, affected insurers and health plans must submit a plan to the Maryland Insurance Administration describing how they will provide adequate access to a broad range of pain management services, including nonopioid drugs and nonpharmacologic, nonoperative alternatives. The Insurance Administration must review those plans for compliance and for any policies that may unduly favor opioid drugs. The bill’s insurance provisions would apply to policies and contracts issued, delivered, or renewed on or after January 1, 2026, while the Medicaid-related provisions would take effect July 1, 2026.
SB 974 would amend the Health – General and Insurance Articles to create new parity requirements for pain-treatment coverage. It would add a Medicaid coverage mandate for FDA-approved nonopioid pain drugs and prohibit the Maryland Medical Assistance Program from imposing more restrictive utilization management on those drugs than on opioid or narcotic pain drugs. It would also create a new insurance section requiring comparable coverage and prior-authorization treatment for nonopioid pain medications in the commercial market, including plans administered through pharmacy benefit managers. In addition, it would require plan submissions to the Maryland Insurance Administration and give the agency a compliance-review role.
No committee transcripts or recorded votes were provided, so there is no direct evidence of debate, support, or opposition in the available materials. Based on the bill text, the measure appears to be framed as a patient-access and opioid-alternative policy, suggesting a generally pro-access and public-health-oriented intent. The absence of recorded votes or hearing testimony means the overall sentiment cannot be assessed beyond the bill’s stated purpose.
The main policy issue is whether nonopioid pain medications should receive the same or better coverage treatment than opioid or narcotic drugs. Potential points of contention include the bill’s limits on insurer and Medicaid utilization management tools such as prior authorization, step therapy, and fail-first protocols, which payers often use to control costs and guide prescribing. Another possible area of dispute is the requirement that plans submit access and coverage strategies to the Maryland Insurance Administration, which could be viewed as an added regulatory burden. No specific stakeholders were identified in the provided record, but likely interested parties include insurers, managed care organizations, pharmacy benefit managers, Medicaid administrators, pain patients, and opioid-safety advocates.